Medicine and HealthNature Communications
An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants
W. Tai, S. Feng, et al.
This innovative study by Wanbo Tai and colleagues introduces a groundbreaking mRNA-based vaccine that effectively targets conserved regions of the SARS-CoV-2 virus. By focusing on T-cell responses and combining it with existing RBD-based vaccines, this research shows promising results against emerging variants, underscoring the importance of robust immune response for effective COVID-19 vaccination.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
P. Jalkanen, P. Kolehmainen, et al.
Medicine and Health
saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
M. Komori, T. Nogimori, et al.
Medicine and Health
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts
R. Kundu, J. S. Narean, et al.
Medicine and Health
Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants
Y. Kang, C. Sun, et al.
